Family First Health

Pharmacy Market

TrialCard | August 31, 2021

TrialCard Incorporated today announced the launch of Engage HCP by TrialCard, a new expanded suite of services that serves as a complement to a biopharma brand's field teams, while delivering measurable results in brand reach, lead generation, and market share growth. Engage HCP by TrialCard is designed to offer a flexible array of services that can serve as standalone teams or be used to bolster the efforts of existing field teams. Engage HCP offers HCP engagement servi...

PHARMACY MARKET, PHARMA TECH

Tetra Bio-Pharma Inc. | December 07, 2022

Tetra Bio-Pharma Inc. a leader in cannabinoid-derived drug discovery and development announced significant results from the study of Onternabez combined with Favipiravir against ARDS powered platform which purposely integrates target identification, validation, lead discovery optimization, drug synthesis, and preclinical testing. Leveraging the power of AI enables more answers and greater insights, faster. Results from the study demonstrate that Tetra's investigational therape...

Pharmacy Market

Businesswire | July 07, 2023

Cytel Inc., provider of quantitative insights and health data analytics to leaders in life sciences, has acquired stève consultants, specialists in market access, real-world (RWE), and health economics and outcomes research (HEOR). The acquisition further expands Cytel’s real-world & advanced analytics (RWAA) capabilities, giving sponsors an expanded global offering, with access to additional specialists and localized expertise. This acquisition continues the company&rsquo...

Pharma Tech

Bayer and Mammoth Biosciences | January 10, 2022

Bayer AG and Mammoth Biosciences, Inc., which is harnessing the diversity of nature to power the next-generation CRISPR products, announced a strategic collaboration and option agreement for the use of Mammoth’s CRISPR systems to develop in vivo gene-editing therapies. Mammoth Biosciences’ groundbreaking gene-editing technology is a key enabling technology, as well as a stand-alone therapeutic modality. It will significantly enhance Bayer’s efforts to develop tra...